Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations, 2015 we hereby submit the intimation towards the adoption of New Line(s) of Business and Product Development / Product ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lactose India Ltd is expanding into value-added pharmaceutical excipients, specifically specialised grades of pharmaceutical lactose, moving beyond its regular pharma-grade offerings. The company has invested approximately ₹15 crore in plant & machinery, process development, and related infrastructure for this new line. Four new products — Spray Dried Lactose, Anhydrous Lactose, Homoeopathic Grade Lactose, and Inhalation Grade Lactose — have been developed, with trial runs completed and selective customer supplies already commenced following customer-specific validation. The primary focus is the domestic pharmaceutical market, with international markets possible later subject to commercial and regulatory feasibility. The strategy aims to reduce dependence on imported specialised lactose, complete the product basket for customer retention, and improve margins.
Positive for long-term shareholders as the move up the value chain could lift margins and reduce import-related risks, though execution and validation timelines with pharmaceutical customers remain key near-term watchpoints.